N/A N=57 MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Healthy Volunteers
Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=7 CGM Use in Islet Transplant Recipients
Islet Transplantation · Type1 Diabetes Mellitus
Primary: Percentage Time in Range 70-180 mg/dL by CGM — 77 percentage of CGM readings 70-180mg/dL
N/A N=63 The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse
Insomnia
Primary: Change in Insomnia Severity Index - Total Score — -10.71; -8.84; -8.51; -9.30 units on a scale
N/A N=44 Cocoa to Improve Walking Performance in Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change From Baseline in Six-minute Walk Distance — 18.4; -24.2; 15.1; -2.9 meters
Phase 3 N=338 A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
Rheumatoid Arthritis (RA)
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 31.4; 71.6 percentage of participants — p=<0.001
Phase 2 N=15 Alpha Lipoic Acid in Geographic Atrophy
Age-Related Macular Degeneration
Primary: Phase I: Percentage of Participants With Adverse Events — 11; 10; 10 Participants — p=1.00
Phase 2 N=72 Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Glioblastoma · Glioblastoma Multiforme · Gliosarcoma
Primary: Phase 1- Determination of the Maximum Tolerated Dose (MTD) of Enzastaurin — 250 milligrams (mg)
Phase 2 N=80 Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
Acute Pancreatitis · Intra-abdominal Hypertension
Primary: Percent Change of IAP After Treatment — -18.7; -5.4; -27.2; -20.0 percent change of IAP
Phase 3 N=156 Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion
Abortion in First Trimester
Primary: Worst Pain Measurement Via Numeric Rating Scale (NRS-11) — 8.0; 7.0; 7.5; 6.5 score on a scale — p=.20
Phase 1 N=29 Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
Hypertension, Pulmonary
Primary: Maximum Observed Plasma Concentration (Cmax) After Administration of AMB Under Fasted Condition — 359.030; 316.505; 353.252 Nanogram per milliliter
Phase 2 N=74 A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 11.1 Months
Phase 2 N=149 Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
Avian Influenza · Influenza · Influenza Immunisation
Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Against the 2017 H7N9 Inactivated Influenza Vaccine (IIV) Strain After Second H7N9…
N/A N=49 A Pilot Study to Evaluate the Feasibility and Potential Effectiveness of the Flexitouch System Head and Neck Treatment
Head and Neck Neoplasms · Head and Neck Cancer · Head and Neck Lymphedema
Primary: Fidelity/Adherence Via Subject Diary — 5; 1; 1; 2 Participants
N/A N=29 Role of the Gut Microbiome on Lean Mass and Physical Function in Older Adults
Sarcopenia
Primary: Percentage of Whole Body Lean Mass (%WBLM) — 67.3; 61.9 % of whole body mass
N/A N=17 PREVAIL-20J - Transfemoral Placement of 20mm Aortic Balloon Expandable Transcatheter Valve Trial
Aortic Valve Stenosis
Primary: NYHA Improvement and AVA >= 0.65 cm2 — 14 Participants